In addition, downregulation of FXR results in elevated expression of β-catenin along with its downstream targets c-Myc and cyclin D1, which promotes tumor cell proliferation and invasion capacity, and this mechanism may exhibit a close association with sorafenib resistance [72, 73]. The gene discussed is NR1H4; the disease is neoplasm.